PURE Bioscience (PURE) Reports 2012 Fiscal Year End Results  
10/30/2012 7:45:41 AM

SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2012 (“fiscal 2012”).

Revenue for fiscal 2012 was $812,000, compared with revenue of $454,000 for the year ended July 31, 2011 (“fiscal 2011”). The fiscal 2012 revenues of $812,000 exclude fiscal fourth quarter product shipments of $273,000 which will be reported to revenues in the future as customer payments are received. The net loss for fiscal 2012 was $8,890,000 or $1.58 per share, compared with a net loss of $8,349,000, or $1.79 per share, in fiscal 2011.